欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Senexin B_1449228-40-3_产品详情
1449228-40-3
  • names:

    Senexin B

  • CAS号:

    1449228-40-3

    MDL Number:
  • MF(分子式): C27H26N6O MW(分子量): 450.53
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Senexin B
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM002259-5mg 5mg 99.7% ¥ 4050.00 ¥ 4050.00 2-3天
- +
¥ 0.00
YZM002259-1mg 1mg 99.7% ¥ 1560.00 ¥ 1560.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 1449228-40-3
Inchi
InchiKey
分子式 Formula C27H26N6O
分子量 Molecular Weight 450.53
溶解度Solubility 生物体外In Vitro:DMSO溶解度6 mg/mL(13.32 mM;Need ultrasonic and warming)
性状
储藏条件 Storage conditions 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月
Senexin B(CAS:1449228-40-3)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Senexin B 为有效的,高水溶性,具有口服活性的CDK8/19抑制剂,对 CDK8 和 CDK19 的Kd值分别为 140 nM 和 80 nM
IntroductionSenexin B is a potent, highly wateroluble and bioavailableCDK8/19inhibitor, withKds of 140 nM for CDK8 and 80 nM for CDK19.
Application1
Application2
Application3
Senexin B 为有效的,高水溶性,具有口服活性的CDK8/19抑制剂,对 CDK8 和 CDK19 的Kd值分别为 140 nM 和 80 nM。Senexin B is a potent, highly water-soluble and bioavailableCDK8/19inhibitor, withKds of 140 nM for CDK8 and 80 nM for CDK19.
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Porter D, et al. Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19. Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr PR08. doi:10.1158/1538-7445.CHTME14-PR08
【2】.McDermott MS, et al. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget. 2017 Feb 21;8(8):12558-12575.
【3】.CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer. US 9321737 B2
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents